Methodological issues for biomarkers and intermediate outcomes in cohort studies

Epidemiologic Reviews

Volumn 20, Issue 1, 1998, Pages 29-42

  Muñoz, Alvaro ^a   Gange, Stephen J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CD4 ANTIGEN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; NEOPTERIN; PROTEIN P53;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARCINOGENESIS; COHORT ANALYSIS; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; HUMAN; INJURY; METHODOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW;

EID: 0031658148     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017970     Document Type: Review

References (74)

1. Schulte PA, Perera FP. Molecular epidemiology: principles and practice. San Diego, CA: Academic Press, 1993.
2. Hulka BS, Wilcosky TC, Griffith JD. Biological markers in epidemiology. New York, NY: Oxford University Press, 1990.
3. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994;3:3-10.
4. Kensler TW, Groopman JD, Wogan GN. Carcinogen-DNA and protein adduct biomarkers for cohort selection and as modifiable endpoints in chemoprevention trials. In: Stewart BW, McGregor D, Kleihues P, eds. Principles of chemoprevention. Lyon, France: International Agency for Research on Cancer, 1996: 237-45. (IARC scientific publications no. 139).
5. Kensler TW, Gange SJ, Egner PA, et al. Predictive value of molecular dosimetry: individual versus group effects of Oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol Biomarkers Prev 1997;6:603-10.
6. Groopman JD. Molecular dosimetry methods for assessing human aflatoxin exposures. In: Eaton DL, Groopman JD, eds. The toxicology of aflatoxins: human health, veterinary, and agricultural significance. San Diego, CA, Academic Press, 1994:259-79.
7. Hunter DJ. Methodological issues in the use of biological markers in cancer epidemiology: cohort studies. In: Toniolo P, Boffetta P, Shuker DEF, et al., eds. Application of biomarkers in cancer epidemiology. Lyon, France: International Agency for Research on Cancer, 1997:39-46. (IARC scientific publications no. 142).
8. Kingsley LA, Detels R, Kaslow R, et al. Risk factors for seroconversion to human immunodeficiency virus among male homosexuals: results from the Multicenter AIDS Cohort Study. Lancet 1987;1:345-9.
9. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
10. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
11. Lang W, Perkins H, Anderson RE, et al. Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr 1989;2:63-9.
12. Margolick JB, Muñoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection: the Multicenter AIDS Cohort Study. Nat Med 1995;1:674-80.
13. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997;3:23-36.
14. Checkoway H, Pearce NE, Crawford-Brown DJ. Research methods in occupational epidemiology. New York, NY: Oxford University Press, 1989.
15. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York, NY: Oxford University Press, 1994.
16. Rosner B, Muñoz A. Conditional linear models for longitudinal data. In: Dwyer JH, Feinleib M, Lippert P, et al., eds. Statistical models for longitudinal studies of health. New York, NY: Oxford University Press, 1992:115-31.
17. Bacchetti P. Estimating the incubation period of AIDS by comparing population infection and diagnosis patterns. J Am Stat Assoc 1990;85:1002-8.
18. Bacchetti P, Jewell NP. Nonparametric estimation of the incubation period of AIDS based on a prevalent cohort with unknown infection times. Biometrics 1991;47:947-60.
19. Hendriks JCM, Medley GF, van Griensven GJP, et al. The treatment-free incubation period of AIDS in a cohort of homosexual men. AIDS 1993;7:231-9.
20. Gauvreau K, DeGruttola V, Pagano M, et al. The effect of covariates on the induction time of AIDS using improved imputation of exact seroconversion times. Stat Med 1994;13: 2021-30.
21. Farewell VT, Coates RA, Fanning MM, et al. The probability of progression to AIDS in a cohort of male sexual contacts of men with HIV disease. Int J Epidemiol 1992;21:131-5.
22. Muñoz A, Carey V, Taylor JMG, et al. Estimation of time since exposure for a prevalent cohort. Stat Med 1992;11: 939-52.
23. Alcabes P, Muñoz A, Vlahov D, et al. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Ann Epidemiol 1994;4:17-26.
24. Alcabes P, Muñoz A, Vlahov D, et al. Incubation period of human immunodeficiency virus. Epidemiol Rev 1993;15: 303-18.
25. Donahue JG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
26. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997;337:1491-9.
27. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clin Immunol Immunopathol 1990;55:173-86.
28. Farzadegan H, Vlahov D, Solomon L, et al. Detection of human immunodeficiency virus type 1 infection by polymerase chain reaction in a cohort of seronegative intravenous drug users. J Infect Dis 1993;168:327-31.
29. Kirby AJ, Muñoz A, Detels R, et al. Thrush and fever as measures of immunocompetence in HIV-1-infected men. J Acquir Immune Defic Syndr 1994;7:1242-9.
30. Rosner B, Willett WC, Spiegelman D. Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat Med 1989; 8:1051-69.
31. Carroll RJ, Ruppert D, Stefanski LA. Measurement error in nonlinear models. London, England: Chapman and Hall, 1995.
32. Little RJA, Rubin DB. Statistical analysis with missing data. New York, NY: Wiley, 1987.
33. Muñoz A, Carey V, Saah AJ, et al. Predictors of decline in CD4 lymphocytes in a cohort of homosexual men infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1988;1:396-404.
34. Miller RG Jr. Survival analysis. New York, NY: Wiley, 1981.
35. Cox DR, Oakes D. Analysis of survival data. New York, NY: Chapman and Hall, 1984.
36. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322: 166-72.
37. Albert JM, Ioannidis JPA, Reichelderfer P, et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. Stat Med 1998 (in press).
38. Lawless JF. Statistical models and methods for lifetime data. New York, NY: Wiley, 1982.
39. Muñoz A, Townsend TR. Design and analytical issues in studies of infectious diseases. In: Wenzel RP, ed. Prevention and control of nosocomial infections. 3rd ed. Baltimore, MD: Williams and Wilkins, 1997:215-29.
40. Ciampi A, Lawless JF, McKinney SM, et al. Regressive and recursive partition strategies in the analysis of medical survival data. J Clin Epidemiol 1988;41:737-48.
41. Segal MR. Regression trees for censored data. Biometrics 1988;44:35-47.
42. Muñoz A, Sunyer J. Comparison of semiparametric and parametric survival models for the analysis of bronchial responsiveness. Am J Respir Crit Care Med 1996;154:S234-9.
43. Miller RG Jr. What price Kaplan-Meier? Biometrics 1983;39: 1077-81.
44. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 1992;11:1871-9.
45. Gail M. Use of observational data for evaluating AIDS therapies. In: Finkelstein DM, Schoenfeld DA, eds. AIDS clinical trials. New York, NY: Wiley-Liss, 1995:403-22.
46. Muñoz A, Hoover DR. Use of cohort studies for evaluating AIDS therapies. In: Finkelstein DM, Schoenfeld DA, eds. AIDS clinical trials. New York, NY: Wiley-Liss, 1995: 423-46.
47. Lamarca R, Alonso J, Gomez G, et al. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly. J Gerontol A Biol Sci Med Sci (in press).
48. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on the natural history of HIV/ AIDS in a large cohort of seroconverters. JAMA 1998 (in press).
49. Clayton D, Hills M. Statistical models in epidemiology. New York, NY: Oxford University Press, 1993.
50. Zolla-Pazner S, Des Jarlais DC, Friedman SR, et al. Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. Proc Natl Acad Sci USA 1987; 84:5404-8.
51. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann Intern Med 1971;74:1-12.
52. Fletcher C, Peto R, Tinker C, et al. The natural history of chronic bronchitis and emphysema. New York, NY: Oxford University Press, 1976.
53. Samet J, Muñoz A. Evolution of the cohort study. Epidemiol Rev 1998;20:1-14.
54. Detels R, Phair JP, Saah AJ, et al. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. Jpn J Epidemiol 1992;2(Suppl):S11-19.
55. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology 1998; 9:117-25.
56. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11:167-78.
57. Prentice RL. Surrogate end points in clinical trials: definitions and operational criteria. Stat Med 1989;8:431-40.
58. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125: 605-13.
59. Kirby AJ, Galai N, Muñoz A. Sample size estimation using repeated measurements on biomarkers as outcomes. Control Clin Trials 1994;15:165-72.
60. Kelsey JL, Thompson WD, Evans AS, et al. Methods in observational epidemiology. New York, NY: Oxford University Press, 1996.
61. Muñoz A, Kirby AJ, He YD, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:496-505.
62. Gange SJ, Muñoz A, Schrager LK, et al. Design of nested studies to identify factors related to late progression of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(Suppl 1):S5-9.
63. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996;157:2168-73.
64. 2-microglobulin: Multicenter AIDS Cohort Study. J Infect Dis 1997;176:1161-7.
65. Gange SJ, Mellors JW, Schrager L, et al. Longitudinal viral RNA patterns among HIV-1-infected individuals with late disease progression. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998. (Abstract 12).
66. Pendergast J, Gange SJ, Lindstrom ML, et al. A survey of methods for analyzing clustered binary data. Int Stat Rev 1996;64:89-118.
67. Jennrich RI, Schluchter MD. Unbalanced repeated-measure models with structured covariance matrices. Biometrics 1986: 42:805-20.
68. Gange SJ, Saez M, Alonso J, et al. Use of the beta-binomial distribution to model the effect of policy on appropriateness of hospital stays. Appl Stat 1996;45:371-82.
69. Prentice RL, Zhao LP. Estimating equations for parameters in means and covariances of multivariate discrete and continuous responses. Biometrics 1991;47:825-39.
70. Twisk JWR, Kemper HCG, Mellenbergh GJ. Mathematical and analytical aspects of tracking. Epidemiol Rev 1994;16: 165-83.
71. Gange SJ, Jacobson LP, Muñoz A. Parametric models to assess tracking of categorical high-risk sexual behaviour for HIV infection. Stat Med 1996;15:2323-36.
72. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. New York, NY: Oxford University Press, 1993.
73. Yang Q, Khoury MJ, Flanders WD. Sample size requirements in case-only designs to detect gene-environment interaction. Am J Epidemiol 1997;146:713-20.
74. Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339: 943-6.